HROW logo

HROW
Harrow Health Inc

3,418
Mkt Cap
$1.42B
Volume
5.4M
52W High
$54.85
52W Low
$24.62
PE Ratio
-232.66
HROW Fundamentals
Price
$29.03
Prev Close
$38.04
Open
$33.87
50D MA
$37.64
Beta
1.46
Avg. Volume
479,214.15
EPS (Annual)
-$0.1398
P/B
27.00
Rev/Employee
$730,034.85
$1,979.96
Loading...
Loading...

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available

Earnings Recap

• Reported GAAP EPS of -$0.74 down -48.00% YoY • Reported revenue of $44.2M down -7.59% YoY • Harrow reaffirmed its full-year 2026 revenue guidance at $350M to $365M and expects second quarter revenue between $71 million and $81 million for Harrow.

Bullish

Harrow's VEVYE achieved record prescription performance and surpassed XIIDRA, while IHEEZO and TRIESENCE demonstrated strong unit demand growth, positioning Harrow for future revenue benefits.

Bearish

Harrow reported a Q1 2026 net loss of -$27.6M, exacerbated by an $8M gross-to-net revenue adjustment for VEVYE, while the overall branded dry eye market declined.

Latest HROW News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.